Titan Pharmaceuticals Announces Confirmation of Meeting With FDA Regarding …

Published October 18, 2013

Titan Pharmaceuticals Announces Confirmation of Meeting With FDA Regarding …
Before the year 2000, medication-assisted therapies for opioid dependence had been sanctioned to a limited number of facilities in the U.S. The Drug Addiction Treatment Act of 2000 (DATA 2000) allowed medical office-based treatment of opioid dependence … Read more on MarketWatch

TITAN PHARMACEUTICALS, INC. : September 26, 2013 – Titan …
Before the year 2000, medication-assisted therapies for opioid dependence had been sanctioned to a limited number of facilities in the U.S. The Drug Addiction Treatment Act of 2000 (DATA 2000) allowed medical office-based treatment of opioid dependence … Read more on 4-traders (press release)

Combining RNAi and in vivo confocal microscopy analysis of the …
Clinical approaches for tumor treatment often rely on combination therapy where a DNA damaging agent is used in combination with a DNA repair protein inhibitor. For this reason … Unfortunately, when studying these drug candidates, classical … Read more on BioTechniques.com